This site is intended for healthcare professionals
News

MHRA approves Ad26.COV2-S [recombinant] for active immunisation against COVID-19 within the United Kingdom - Janssen.

Read time: 1 mins
Last updated:24th Sep 2021
Published:29th May 2021
Ad26.COV2-S [recombinant] a single-dose coronavirus vaccine from Janssen, part of Johnson & Johnson, has been approved by the MHRA (UK) and is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

Ad26.COV2-S [recombinant], has been shown to be 67% effective overall at preventing moderate to severe COVID-19 compared with placebo. The phase III ENSEMBLE trials demonstrated that the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination.

Condition: Coronavirus/COVID-19 Infection
Type: drug